Menu

Back

Professor Maria Grazia Spillantini FRS FMedSci

University Position
Professor

Interests

Our interest is in the identification of the mechanisms leading to neuronal death and clinical phenotype in diseases such as Alzheimer's disease, Parkinson's disease and frontotemporal dementia. In particular we study the role of microtubule-associated protein tau and alpha-synuclein aggregation in the pathogenesis of tauopathies and alpha-synucleinopathies. Our work extends from genetic studies in patients to disease models. The aim is to identify mechanism-based therapies for these disorders.

Key Publications

Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson’s disease.

DOI: http://doi.org/10.1002/ana.21192
Journal: Ann Neurol
E-pub date: 31 Aug 2007
Authors: A Goris, CH Williams-Gray, GR Clark, T Foltynie, SJG Lewis, J Brown, M Ban, MG Spillantini, A Compston, DJ Burn, PF Chinnery, RA Barker, SJ Sawcer

Publications

In Vivo 18F-Flortaucipir PET Does Not Accurately Support the Staging of Progressive Supranuclear Palsy.

DOI: http://doi.org/10.2967/jnumed.121.262985
Journal: J Nucl Med
E-pub date: 1 Jul 2022
Authors: M Malpetti, SS Kaalund, KA Tsvetanov, T Rittman, M Briggs, KSJ Allinson, L Passamonti, N Holland, PS Jones, TD Fryer, YT Hong, A Kouli, WR Bevan-Jones, E Mak, G Savulich, MG Spillantini, FI Aigbirhio, CH Williams-Gray, JT O'Brien, JB Rowe

The microglial P2Y6 receptor mediates neuronal loss and memory deficits in neurodegeneration.

DOI: http://doi.org/10.1016/j.celrep.2021.110148
Journal: Cell Rep
E-pub date: 28 Dec 2021
Authors: M Puigdellívol, S Milde, A Vilalta, TOJ Cockram, DH Allendorf, JY Lee, JM Dundee, K Pampuščenko, V Borutaite, HN Nuthall, JH Brelstaff, MG Spillantini, GC Brown

Validation of the new pathology staging system for progressive supranuclear palsy.

DOI: http://doi.org/10.1007/s00401-021-02298-z
Journal: Acta Neuropathol
E-pub date: 1 May 2021
Authors: M Briggs, KSJ Allinson, M Malpetti, MG Spillantini, JB Rowe, SS Kaalund

Regional expression of the MAPT gene is associated with loss of hubs in brain networks and cognitive impairment in Parkinson disease and progressive supranuclear palsy.

DOI: http://doi.org/10.1016/j.neurobiolaging.2016.09.001
Journal: Neurobiol Aging
E-pub date: 1 Dec 2016
Authors: T Rittman, M Rubinov, PE Vértes, AX Patel, CE Ginestet, BCP Ghosh, RA Barker, MG Spillantini, ET Bullmore, JB Rowe

[18F]AV-1451 PET in behavioral variant frontotemporal dementia due to MAPT mutation.

DOI: http://doi.org/10.1002/acn3.366
Journal: Ann Clin Transl Neurol
E-pub date: 1 Dec 2016
Authors: WR Bevan Jones, TE Cope, L Passamonti, TD Fryer, YT Hong, F Aigbirhio, JJ Kril, SL Forrest, K Allinson, JP Coles, P Simon Jones, MG Spillantini, JR Hodges, JT O'Brien, JB Rowe

Genetic and pathological links between Parkinson’s disease and the lysosomal disorder Sanfilippo syndrome.

DOI: http://doi.org/10.1002/mds.24029
Journal: Mov Disord
E-pub date: 1 Feb 2012
Authors: SE Winder-Rhodes, P Garcia-Reitböck, M Ban, JR Evans, TS Jacques, A Kemppinen, T Foltynie, CH Williams-Gray, PF Chinnery, G Hudson, DJ Burn, LM Allcock, SJ Sawcer, RA Barker, MG Spillantini